MedPath

Pregabalin

Generic Name
Pregabalin
Brand Names
Lyrica, Pregabalin Accord, Pregabalin Pfizer, Pregabalin Sandoz, Pregabalin Mylan, Pregabalin Zentiva
Drug Type
Small Molecule
Chemical Formula
C8H17NO2
CAS Number
148553-50-8
Unique Ingredient Identifier
55JG375S6M
Background

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions. Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release). It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.

Indication

Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.

Associated Conditions
Diabetic Peripheral Neuropathic Pain (DPN), Epilepsies, Fibromyalgia, Generalized Anxiety Disorder, Neuropathic Pain, Partial-Onset Seizures, Peripheral Neuropathic Pain, Peripheral neuropathy, Postherpetic Neuralgia
Associated Therapies
-
Clinical Trials
Related News

Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement

Completed
Conditions
Neuropathic Pain
Postoperative Pain
Interventions
Other: Naive patient
Drug: Pregabalin
First Posted Date
2016-08-15
Last Posted Date
2018-04-03
Lead Sponsor
Christophe Aveline, MD
Target Recruit Count
70
Registration Number
NCT02866396
Locations
🇫🇷

Christophe Aveline, MD, Cesson Sevigne, France

Prophylactic Pregabalin to Decrease Pain During Medical Abortion

Phase 4
Completed
Conditions
Acute Pain
Interventions
Drug: Placebo
Drug: Pregabalin
First Posted Date
2016-05-25
Last Posted Date
2018-04-19
Lead Sponsor
University of Hawaii
Target Recruit Count
110
Registration Number
NCT02782169
Locations
🇺🇸

Women's Options Center, Honolulu, Hawaii, United States

Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?

Phase 2
Completed
Conditions
Dry Eye
Interventions
Drug: Placebo
Drug: Pregabalin
First Posted Date
2016-03-08
Last Posted Date
2019-11-14
Lead Sponsor
University of Miami
Target Recruit Count
43
Registration Number
NCT02701764
Locations
🇺🇸

Anat Galor, Miami, Florida, United States

The Effect of Pregabalin on the Spinal Anesthesia

Not Applicable
Completed
Conditions
Block
Interventions
Drug: Placebo
Drug: Pregabalin
First Posted Date
2016-02-24
Last Posted Date
2016-05-18
Lead Sponsor
Kyungpook National University Hospital
Target Recruit Count
44
Registration Number
NCT02690506
Locations
🇰🇷

Kyungpook National University Hospital, Daegu, Korea, Republic of

Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

Phase 2
Withdrawn
Conditions
Neuropathic Pain
Diabetes
Interventions
Drug: DS-1971a
Drug: placebo
Drug: pregabalin
First Posted Date
2016-02-04
Last Posted Date
2016-07-27
Lead Sponsor
Daiichi Sankyo
Registration Number
NCT02673866

Shifting Pain Modulation From Pro-to Anti-nociceptive

Not Applicable
Terminated
Conditions
Post-operative Chronic Pain
Interventions
Drug: Placebo
Drug: Duloxetine
Drug: Pregabalin
First Posted Date
2016-02-03
Last Posted Date
2017-09-28
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
9
Registration Number
NCT02672202

The Effect of Pregabalin on Pain of Propofol Injection

Not Applicable
Completed
Conditions
Pain
Interventions
Drug: Lidocaine
Drug: Pregabalin
Drug: propofol
First Posted Date
2016-01-29
Last Posted Date
2016-05-11
Lead Sponsor
Kyungpook National University Hospital
Target Recruit Count
120
Registration Number
NCT02668094
Locations
🇰🇷

Kyungpook National University Hospital, Daegu, Korea, Republic of

Brain Response to Single Dose of Pregabalin in Fibromyalgia

Phase 2
Completed
Conditions
Fibromyalgia
Interventions
Other: Placebo
Drug: Pregabalin
First Posted Date
2015-12-24
Last Posted Date
2018-02-08
Lead Sponsor
Hospital de Clinicas de Porto Alegre
Target Recruit Count
27
Registration Number
NCT02639533

Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy

Phase 2
Completed
Conditions
Idiopathic Small Fiber Neuropathy
Interventions
Drug: Placebo
Drug: Pregabalin
First Posted Date
2015-11-18
Last Posted Date
2018-10-04
Lead Sponsor
Johns Hopkins University
Target Recruit Count
11
Registration Number
NCT02607254
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

Efficacy of Pregabalin on Chronic Cough

Phase 1
Conditions
Cough
Interventions
Drug: Control-Placebo
Drug: Pregabalin
First Posted Date
2015-06-26
Last Posted Date
2020-09-25
Lead Sponsor
Ottawa Hospital Research Institute
Target Recruit Count
40
Registration Number
NCT02482818
Locations
🇨🇦

The Ottawa Hospital (General and Civic Campuses), Ottawa, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy